When the Options Change for AD, Do the Decisions Change?

Topical therapies remain an essential part of atopic dermatitis management, but their limitations are not always defined by a lack of efficacy. Sometimes the problem is treatment burden, tolerability, or the sheer extent of disease. In this conversation, Mona Shahriari, MD, and E. James Song, MD, examine how clinicians can recognize these limitations earlier and weigh the consequences of prolonged uncontrolled inflammation against the risks of systemic treatment.

Their discussion moves beyond the skin, considering the cumulative effects of AD on quality of life, growth and development in pediatric patients, and the broader spectrum of type 2 inflammatory comorbidities. They also explore how an understanding of IL-4, IL-13, and related pathways can inform therapeutic selection, alongside disease phenotype, prior treatment response, comorbidities, and patient preferences. Looking ahead, Drs Shahriari and Song consider the promise of more precise, individualized treatment approaches and the questions that remain as the therapeutic landscape continues to evolve.